Biotech Investors & VC Firms in New York City
12 firms in this list, with a median first check of $500K. 2 of them lead rounds. Generated from verified public data and updated continuously.
Able Partners
New York CitySeed–Series A$500K – $3M
3 people
Partnership Fund for NYC
New York CitySeed–Growth
9 people
Swell Partners
New York CityPre-Seed–Series A$500K – $600K
3 people
Access Biotechnology
New York CitySeed–Late Stage
2 people
Legendary Ventures, Llc.
New York CitySeed–Late Stage
7 people
Interlagos
New York City
1 person
Seldor Capital
New York CitySeed–Series A
4 people
Lux Capital
New YorkPre-Seed–Growth$100K – $100M
47 people
Deerfield Management Company
New YorkGrowth–Late Stage
88 people
Catalio Capital Management, LP
New YorkSeed–Late Stage
39 people
Easton Capital
New YorkSeed–Late Stage$10M – $20M
7 people
Syno Capital, LLC
New YorkSeries A
4 people
Frequently asked questions
- Who are the top biotech investors & vc firms in new york city?
- Top biotech investors & vc firms in new york city include Able Partners, Partnership Fund for NYC, Swell Partners, Access Biotechnology, Legendary Ventures, Llc., Interlagos, Seldor Capital, Lux Capital — 12 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in new york city?
- The median first check among the 12 biotech investors & vc firms in new york city tracked here is $500K.
- How many biotech investors & vc firms in new york city lead rounds?
- 2 of the 12 biotech investors & vc firms in new york city tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (14074)Investors & VC Firms in United States (13215)Investors & VC Firms in Europe (5565)Crypto & Web3 Investors & VC Firms (4819)Investors & VC Firms in Global (4147)SaaS Investors & VC Firms (3842)AI & Machine Learning Investors & VC Firms (3754)Fintech Investors & VC Firms (3710)Investors & VC Firms in Asia-Pacific (3567)Healthtech Investors & VC Firms (3393)
Data sourced from public filings and firms' own websites — see our methodology.






























